Search Results 21-30 of 17001 for hla genotype

  1. Clinical trials - Oncology (Medical)

    The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 6 months of documentation of HLA-A LOH status; The percentage ...

  2. rs7903146 genotype on islet GLP-1 production in humans - Mayo Clinic

    The purpose of this study is to determine the contribution of islet GLP-1 to islet function in people with and without diabetes-associated genetic variation in ...

  3. A Study To Evaluate The Safety And Efficacy Of A2B395, An Allogeneic Logic-gated CAR T, In Participants With Solid Tumors That Express EGFR And Have Lost HLA-A*02 Expression - Mayo Clinic

    A Study To Evaluate The Safety And Efficacy Of A2B395, An Allogeneic Logic-gated CAR T, In Participants With Solid Tumors That Express EGFR And Have Lost HLA-A* ...

  4. A Study To Evaluate The Safety And Efficacy Of Mesothelin-Targeting Logic-gated CAR T, In Participants With Solid Tumors That Express MSLN And Have Lost HLA-A*02 Expression - Mayo Clinic

    A Study To Evaluate The Safety And Efficacy Of Mesothelin-Targeting Logic-gated CAR T, In Participants With Solid Tumors That Express MSLN And Have Lost HLA-A* ...

  5. Allogeneic Transplant in HIV Patients (BMT CTN 0903) - Mayo Clinic

    Donor/recipient HLA matching: Related donor ... Unrelated donor: must be a 7/8 or 8/8 match at HLA ... genotype). The results should be included as part ...

  6. Emicizumab In Patients With Acquired Hemophilia A - Mayo Clinic

    HLA genotype in patients with acquired haemophilia A. Pavlova A. A; Zeitler H. H; Scharrer I. I; Brackmann HH. H-H; Oldenburg J. J. Haemophilia : the ...

  7. Clinical trials - Oncology (Medical)

    The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 6 months of documentation of HLA-A LOH status; The percentage ...

  8. Clinical trials - Oncology (Medical)

    The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 6 months of documentation of HLA-A LOH status; The percentage ...

  9. Clinical trials - Oncology (Medical)

    The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 6 months of documentation of HLA-A LOH status; The percentage ...

  10. A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression - Mayo Clinic

    A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression.